AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer
Reuters: Health
British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer.


Comments

Popular posts from this blog

Women in India Report Higher Sleep Deprivation Than Men

Nadda reviews healthcare delivery mechanisms in Rajasthan, Maharashtra

ICMR to roll out multi-state study to expand palliative care access